Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 9/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 9/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24932946 | 0.85 | XDH (0.42) | HSD17B1HSD17B2CHEK2PTGESXDH | |
| SCHEMBL24933589 | 0.82 | XDH (0.49) | HSD17B1HSD17B2CHEK2PARP1XDH | |
| SCHEMBL24933371 | 0.82 | HSD17B1 (0.44) | HSD17B1HSD17B2CHEK2BTK | |
| SCHEMBL29203323 | 0.82 | PARP1 (0.49) | PARP1 | |
| SCHEMBL24933771 | 0.81 | IKBKB (0.42) | HSD17B1HSD17B2PARP1 | |
| SCHEMBL24933202 | 0.81 | HSD17B1 (0.35) | HSD17B1HSD17B2PARP1 | |
| SCHEMBL24933624 | 0.81 | HSD17B1 (0.35) | HSD17B1HSD17B2BTKPARP1 | |
| SCHEMBL29203414 | 0.80 | HSD17B2 (0.37) | HSD17B1HSD17B2CHEK2 | |
| SCHEMBL24933183 | 0.79 | PARP1 (0.46) | PARP1 | |
| SCHEMBL24933484 | 0.77 | HSD17B2 (0.37) | HSD17B1HSD17B2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |